Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of [11C]BMT-136088 and Receptor Occupancy of BMS-986020 in Healthy Subjects
NCT02017730Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bms-986020 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall safety and tolerability of novel tracer [11C]BMT-136088 up to 90 days and Lung LPA1 percentage receptor occupancy of BMS-986020. Started Jan 2014; status: completed.
02
Drugs
bms-986020
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02017730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017730.